Compare STKL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKL | SPRY |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 769.4M | 833.1M |
| IPO Year | 1999 | 2020 |
| Metric | STKL | SPRY |
|---|---|---|
| Price | $6.49 | $8.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.50 | ★ $40.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 186.67 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $817,715,000.00 | $84,278,000.00 |
| Revenue This Year | $6.84 | $90.76 |
| Revenue Next Year | $33.58 | $81.70 |
| P/E Ratio | $49.85 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $3.32 | $6.66 |
| 52 Week High | $6.94 | $18.63 |
| Indicator | STKL | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 47.22 |
| Support Level | $6.43 | $8.05 |
| Resistance Level | $6.52 | $8.63 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 50.00 | 55.36 |
SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own proprietary brands, including SOWN, Dream, and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut, and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada, and Others, out of which it derives maximum revenue from U.S.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.